MetrioPharm AG is a Swiss biotech company developing first-in-class auto-regulated immune modulators targeting the pathologically dysregulated mitochondrial metabolism in macrophages.
MetrioPharm's platform of oral small molecules has demonstrated preclinical & clinical efficacy (three Phase II studies) in several inflammatory and infectious diseases with an excellent safety profile.
As a monotherapy, MetrioPharm's lead candidate MP1032 produces therapeutic effects similar to corticosteroids (cortisone-based therapeutics), but without serious side effects.
MP1032 has demonstrated synergistic/supra-additive effects in combination with an ultra-low dose (10% of the normal dose) of corticosteroids, demonstrating the potential to create a new class of "super corticosteroids" that are more effective and have no serious side effects. For more than 60 years, there have been no major advances in achieving such corticosteroid-sparing therapy and thereby reducing corticosteroid-specific side effects.
In addition, MP1032 has demonstrated a broad host-directed antiviral and antibacterial activity in preclinical studies.
The Company is headquartered in Zurich and has a subsidiary for R&D activities in Berlin.
Company Details
- Employees
- 23
- Founded
- -
- Address
- Bleicherweg 10, Zürich,zürich 8002,switzerland
- Phone
- +41 (44) 515 21 97
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- metriopharm.com
- Keywords
- Representative jobs.
- HQ
- Zürich, Zürich
Metriopharm Questions
Metriopharm's helpline number is +41 (44) 515 21 97
Metriopharm's website is metriopharm.com
Metriopharm's LinkedIn profile is https://ch.linkedin.com/company/metriopharm
Metriopharm has
23 employees.
View email and phone details for 23
employees at Metriopharm.
Metriopharm's industry is
Biotechnology Research
Metriopharm's top competitors are
Biothink Pharma,
Araris Biotech Ag,
Linkster Therapeutics,
Athebio Ag,
Cutiss Ag,
Tolremo Therapeutics,
Numab Therapeutics Ag,
Metriopharm Deutschland Gmbh,
Memo Therapeutics Ag,
Juvabis Ag.
Metriopharm's categories are Biotechnology Research
Metriopharm's founding year is 2007
